Innovative antimetabolites in solid tumours
Author(s)
Bibliographic Information
Innovative antimetabolites in solid tumours
(Monographs / European School of Oncology)
Springer-Verlag, c1994
- : gw
- : us
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references
Description and Table of Contents
Description
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice.
One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.
Table of Contents
Antimetabolites: Historical Perspectives.- Preclinical Characteristics of Cytarabine, Gemcitabine, Fludarabine and Cladribine: Relevance for Clinical Studies.- Thymidylate Synthase Inhibitors, Modulation of 5-Fluorouracil and Folate Analogues.- A Review of Fludarabine and Cladribine in Solid Tumours.- Advanced Breast Cancer: Experience with Gemcitabine.- Gemcitabine in Ovarian Cancer.- Gemcitabine Therapy in Non-Small Cell Lung Cancer: A Review.- Chemotherapy in Advanced Non-Small Cell Lung Cancer. Changes in Performance Status and Tumour-Related Symptoms.- Safety Profile of Gemcitabine, Fludarabine and Cladribine.
by "Nielsen BookData"